Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Amgen's Beating the Market -- Here's Why It's a Buy Now

TheMotleyFool

0 0

Amgen's Beating the Market -- Here's Why It's a Buy Now: https://g.foolcdn.com/editorial/images/686988/biotech-engineers-studying-samples-in-lab.jpg

Amgen (NASDAQ: AMGN) is the world's largest biotechnology company by revenue, focusing on using living cells to create a robust product portfolio of biologic medicines to treat serious diseases in several areas -- among them, cardiovascular, oncology, and neuroscience. In 2022, the company's stock has returned over 9% year to date, outperforming the S&P 500's loss of 20%.

A strong first half of the year amid a bear market is a great reason for investors to be interested in the company's stock. But what might truly excite investors is what could be ahead for Amgen in 2023 and beyond.

Source Fool.com

Like: 0

AMGN

Share